14 August 2018
Visiongain’ has launched a new pharma report Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others
The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth.
The lead analyst of the report commented "Visiongain notes that strong growth is expected in the skin structure infections (SSSI) sector of the dermatological drugs market. The increasing number of immunocompromised patients and the ageing population will contribute to the expansion expected in the segment of the market. We also expect growth to be driven by the development of new antibacterial drugs with better safety and efficacy profiles than existing antibiotics."
Leading companies featured in the report include AbbVie, Amgen, Bayer AG, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK), Johnson & Johnson, LEO Pharma, Merck & Co, Inc., Novartis, Pfizer
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.